<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00259337</url>
  </required_header>
  <id_info>
    <org_study_id>E2I41</org_study_id>
    <nct_id>NCT00259337</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Pentaxim™ in an Indian Population</brief_title>
  <official_title>Immunogenicity and Safety of the Sanofi Pasteur DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM™) Given as a Three-Dose Primary Vaccination at 6, 10, and 14 Weeks of Age and Followed by a Booster Dose at 18-19 Months of Age in Healthy Infants in India.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present clinical study will assess the immunogenicity as the primary objective and the&#xD;
      reactogenicity as the secondary objective of Aventis Pasteur's DTacP-IPV// PRP~T combined&#xD;
      vaccine (Pentavac™ or Pentaxim™) as a three-dose primary vaccination at 6, 10 and 14 weeks of&#xD;
      age followed by a booster dose during the second year of life.&#xD;
&#xD;
      Safety:&#xD;
&#xD;
      This study will describe the safety after each dose of the primary series of the study's&#xD;
      combined vaccine (Pentaxim™).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To provide information concerning the safety of DTacP-IPV//PRP~T combined vaccine</measure>
    <time_frame>19 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">226</enrollment>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <condition>Polio</condition>
  <condition>Pertussis</condition>
  <condition>Haemophilus Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Diphteria/Tetanus/Polio/Acellular Pertussis/Hib vaccine</intervention_name>
    <description>0.5 mL, IM</description>
    <arm_group_label>1</arm_group_label>
    <other_name>PENTAXIM™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 42 to 56 days inclusive on the day of inclusion&#xD;
&#xD;
          -  Born at full term pregnancy (&gt; 37 weeks) with a birth weight ≥ 2.5 kg&#xD;
&#xD;
          -  Informed consent form signed by the parent(s) or other legal representative&#xD;
&#xD;
          -  Able to attend all scheduled visits and to comply with all trial procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in another clinical trial in the 4 weeks preceding the (first) trial&#xD;
             vaccination&#xD;
&#xD;
          -  Planned participation in another clinical trial during the present trial period&#xD;
&#xD;
          -  Congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term&#xD;
             systemic corticosteroids therapy&#xD;
&#xD;
          -  Systemic hypersensitivity to any of the vaccine components or history of a&#xD;
             life-threatening reaction to the trial vaccine or a vaccine containing the same&#xD;
             substances&#xD;
&#xD;
          -  Chronic illness at a stage that could interfere with trial conduct or completion.&#xD;
&#xD;
          -  Blood or blood-derived products received in the past.&#xD;
&#xD;
          -  Any vaccination preceding the trial vaccination (except BCG and hepatitis B)&#xD;
&#xD;
          -  History of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B or Haemophilus&#xD;
             influenza type b (confirmed either clinically, serologically or microbiologically).&#xD;
&#xD;
          -  Previous vaccination against the diphtheria, tetanus, pertussis, poliomyelitis&#xD;
             diseases or Haemophilus influenza type b infection with the trial vaccine or another&#xD;
             vaccine.&#xD;
&#xD;
          -  Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination&#xD;
&#xD;
          -  History of/current seizures&#xD;
&#xD;
          -  Febrile illness (rectal temperature ≥ 38.0°C or axillary temperature ≥ 37.4°C) or&#xD;
             acute illness on the day of inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>56 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>November 24, 2005</study_first_submitted>
  <study_first_submitted_qc>November 24, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2005</study_first_posted>
  <last_update_submitted>April 13, 2012</last_update_submitted>
  <last_update_submitted_qc>April 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diphteria</keyword>
  <keyword>Tetanus</keyword>
  <keyword>Polio</keyword>
  <keyword>Acellular Pertussis</keyword>
  <keyword>Hib</keyword>
  <keyword>Haemophilus influenzae type B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Haemophilus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

